Allopurinol should be avoided in a patient receiving which of the following drugs?
Select Your Answer:
Allopurinol inhibits xanthine oxidase, the enzyme that breaks down mercaptopurine.
Thus, people who take allopurinol should either get a reduced dose of 6-mercaptopurine (6-MP) or discontinue allopurinol.
6-MP is used to treat acute lymphocytic leukemia and acute myelogenous leukemia.
It is used off-label for chronic myelogenous leukemia, Crohn disease, ulcerative colitis, and histiocytosis X.
*eMedicine, Google Scholar, UpToDate, WheelessOnline, and DermNet are not affiliated with StatPearls. We do not control their content or advertising.
Adult Lab Normals
Pediatric Lab Normals
Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study., Lin HC,Daimon M,Wang CH,Ho Y,Uang YS,Chiang SJ,Wang LH,, International journal of cardiology, 2017 Apr 15 [PubMed PMID: 28202260]
Gout - a guide for the general and acute physicians., Abhishek A,Roddy E,Doherty M,, Clinical medicine (London, England), 2017 Feb [PubMed PMID: 28148582]
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment., Shen Z,Tieu K,Wilson D,Bucci G,Gillen M,Lee C,Kerr B,, Clinical pharmacology in drug development, 2017 Jan 11 [PubMed PMID: 28074640]
How to prevent allopurinol hypersensitivity reactions?, Stamp LK,Barclay ML,, Rheumatology (Oxford, England), 2018 Jan 1 [PubMed PMID: 29272508]
HLA-associated drug hypersensitivity and the prediction of adverse drug reactions., Negrini S,Becquemont L,, Pharmacogenomics, 2017 Oct [PubMed PMID: 29017379]
Treatment of Hyperuricemia in Chronic Kidney Disease., Ramirez-Sandoval JC,Madero M,, Contributions to nephrology, 2018 [PubMed PMID: 29393124]
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression., Uchida S,Kumagai T,Chang WX,Tamura Y,Shibata S,, Contributions to nephrology, 2018 [PubMed PMID: 29393121]
Preventive Kidney Stones: Continue Medical Education., Assadi F,Moghtaderi M,, International journal of preventive medicine, 2017 [PubMed PMID: 28966756]
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome., Cairo MS,Thompson S,Tangirala K,Eaddy MT,, Clinical lymphoma, myeloma & leukemia, 2017 Mar [PubMed PMID: 27965022]
Medication adherence among patients with gout: A systematic review and meta-analysis., Scheepers LEJM,van Onna M,Stehouwer CDA,Singh JA,Arts ICW,Boonen A,, Seminars in arthritis and rheumatism, 2017 Oct 7 [PubMed PMID: 29198878]
HLA Genotyping for Allopurinol: Lessons Learned., Petry N,Chavour S,, South Dakota medicine : the journal of the South Dakota State Medical Association, 2017 Oct [PubMed PMID: 28957621]
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout., Plumpton CO,Alfirevic A,Pirmohamed M,Hughes DA,, Rheumatology (Oxford, England), 2017 Oct 1 [PubMed PMID: 28957559]
Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis., Yu KH,Yu CY,Fang YF,, International journal of rheumatic diseases, 2017 Sep [PubMed PMID: 28857441]
Allopurinol Against Progression of Chronic Kidney Disease., Golmohammadi S,Almasi A,Manouchehri M,Omrani HR,Zandkarimi MR,, Iranian journal of kidney diseases, 2017 Jul [PubMed PMID: 28794291]
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients., Janssen CA,Jansen TLTA,Oude Voshaar MAH,Vonkeman HE,van de Laar MAFJ,, Rheumatology international, 2017 Sep [PubMed PMID: 28748426]